Akebia Therapeutics Inc. (AKBA)’s stock is trading at $1.55 at the moment marking a fall of -1.90% from the last session close. As of this writing, shares are priced at -7.19% less than their 52-week high of $1.67, and 543.15% over their 52-week low of $0.24. Based on the past 30-day period, the stock price is -8.58% below the high and +88.19% above the low.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, AKBA’s SMA-200 is $0.7449.
Further, it is important to consider AKBA stock ratios, particularly its price-to-sales ratio over the past twelve months, which stands at 1.02.
How does Akebia Therapeutics Inc. (AKBA) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 3 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.67 in simple terms.
Akebia Therapeutics Inc. (AKBA): Earnings History
If we examine Akebia Therapeutics Inc.’s recent earnings history, in the last quarter ended on 3/30/2023, it posted adjusted earnings per share of -$0.14, slashing the consensus of -$0.15. In other words, it beat the consensus by $0.01, resulting in a 6.70% surprise. In the 3 months period before the previous quarter which was closed on 3/30/2023, the stock recorded adjusted earnings per share of -$0.14 in contrast with the Outlook of -$0.15. That was a difference of $0.01 and a surprise of 6.70%.
Akebia Therapeutics Inc. (AKBA): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of 0.00 and -0.05 with an average Earnings Estimate of -0.03 which is in contrast with the last year earnings estimate of 0.23 and also replicates -113.04% growth rate year over year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Ownership Details
I will give a breakdown of the key shareholders in Akebia Therapeutics Inc. (AKBA). Recent figures show that the company’s insiders hold 1.69% of shares. A total of 82 institutional investors hold shares in the company, making 28.72% of its stock and 29.22% of its float.
Mar 30, 2023, it was reported that the Company’s largest institutional holder is Alerce Investment Management, L.P. holding total of 16.21 million shares that make 8.72% of the company’s total number of shares and are currently priced at 9.08 million.
The securities firm Vanguard Group Inc holds 12.51 million shares of AKBA, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 6.73%, and the holding percentage of shares is valued at 7.01 million.
An overview of Akebia Therapeutics Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Akebia Therapeutics Inc. (AKBA) traded 2,061,922 shares per day, with a moving average of $1.2099 and price change of +0.6300. With the moving average of $1.1629 and a price change of +0.4150, about 2,190,697 shares changed hands on average over the past 50 days. Finally, AKBA’s 100-day average volume is 1,796,389 shares, alongside a moving average of $0.9648 and a price change of +0.5994.
